Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Correction to: Digestive Diseases and Sciences https://doi.org/10.1007/s10620-018-5251-9

The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum.

Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA.

In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below:

Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF.

In Table 2, header ‘Mean HBV DNA change from baseline, log₁₀ IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below.

Table 2 Efficacy results at week 120 by baseline HBeAg status and genotype